166 related articles for article (PubMed ID: 25941175)
1. Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia.
Pecenka CJ; Johansson KA; Memirie ST; Jamison DT; Verguet S
BMJ Open; 2015 May; 5(4):e006402. PubMed ID: 25941175
[TBL] [Abstract][Full Text] [Related]
2. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis.
Verguet S; Olson ZD; Babigumira JB; Desalegn D; Johansson KA; Kruk ME; Levin CE; Nugent RA; Pecenka C; Shrime MG; Memirie ST; Watkins DA; Jamison DT
Lancet Glob Health; 2015 May; 3(5):e288-96. PubMed ID: 25889470
[TBL] [Abstract][Full Text] [Related]
3. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.
Verguet S; Murphy S; Anderson B; Johansson KA; Glass R; Rheingans R
Vaccine; 2013 Oct; 31(42):4902-10. PubMed ID: 23871824
[TBL] [Abstract][Full Text] [Related]
4. Health Gains and Financial Protection from Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from an Extended Cost-Effectiveness Analysis.
Johansson KA; Memirie ST; Pecenka C; Jamison DT; Verguet S
PLoS One; 2015; 10(12):e0142691. PubMed ID: 26650078
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
6. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim.
Megiddo I; Colson AR; Nandi A; Chatterjee S; Prinja S; Khera A; Laxminarayan R
Vaccine; 2014 Aug; 32 Suppl 1():A151-61. PubMed ID: 25091670
[TBL] [Abstract][Full Text] [Related]
8. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.
Bar-Zeev N; Tate JE; Pecenka C; Chikafa J; Mvula H; Wachepa R; Mwansambo C; Mhango T; Chirwa G; Crampin AC; Parashar UD; Costello A; Heyderman RS; French N; Atherly D; Cunliffe NA;
Clin Infect Dis; 2016 May; 62 Suppl 2(Suppl 2):S220-8. PubMed ID: 27059360
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.
Nonvignon J; Atherly D; Pecenka C; Aikins M; Gazley L; Groman D; Narh CT; Armah G
Vaccine; 2018 Nov; 36(47):7215-7221. PubMed ID: 29223486
[TBL] [Abstract][Full Text] [Related]
11. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
14. Health Gains and Financial Protection Provided by the Ethiopian Mental Health Strategy: an Extended Cost-Effectiveness Analysis.
Johansson KA; Strand KB; Fekadu A; Chisholm D
Health Policy Plan; 2017 Apr; 32(3):376-383. PubMed ID: 27935798
[TBL] [Abstract][Full Text] [Related]
15. Health gains and financial protection from human papillomavirus vaccination in Ethiopia: findings from a modelling study.
Portnoy A; Sweet S; Desalegn D; Memirie ST; Kim JJ; Verguet S
Health Policy Plan; 2021 Jun; 36(6):891-899. PubMed ID: 33942850
[TBL] [Abstract][Full Text] [Related]
16. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan.
Anwari P; Debellut F; Pecenka C; Parwiz SM; Clark A; Groman D; Safi N
Vaccine; 2018 Dec; 36(51):7769-7774. PubMed ID: 29107346
[TBL] [Abstract][Full Text] [Related]
17. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
18. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
